Moderna’s Shares Rise Amid Federal Funding Talks for mRNA Bird-Flu Vaccine
Moderna (MRNA) saw its shares rise by 2.4% in premarket trading on Thursday, following news that the U.S. government is on the verge of finalizing a deal to fund a late-stage trial of the company’s mRNA-based bird-flu vaccine.
Read More
Summit Therapeutics Surges Ahead: Ivonescimab Outperforms Keytruda in Landmark Lung Cancer Trial
Shares of Summit Therapeutics Inc. (SMMT) soared by more than 270% on Thursday following the announcement that its investigational cancer drug, ivonescimab, outperformed Merck & Co. Inc.’s (MRK) Keytruda in a late-stage clinical trial.
Read More
From Lab to Market: Insmed’s Brensocatib Sets Sights on FDA Approval
Shares of Insmed Incorporated (INSM) surged on Tuesday, following the announcement of positive results from the final-phase clinical trial of its experimental drug, brensocatib.
Read More
Shareholder Decisions at Innate Pharma’s 2024 Annual General Meeting
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) has announced the results of the voting conducted during its Annual General Meeting (AGM), which took place on May 23, 2024, in Marseille.
Read More
AstraZeneca Aims for $80 Billion in Sales by 2030, Heralding New Growth Era
AstraZeneca (LSE: AZN) has set an ambitious goal to nearly double its sales by 2030, aiming to reach $80 billion by launching 20 new medicines over the next six years.
Read More
Previous slide
Next slide

Get Breaking Market Updates Sent Right to Your Phone

TODAYS TOP STORIES

OUR TRADING BRANDS

LATEST POSTS

This Publication is part of Anchor IR

Trading foreign exchange, stocks, options, or futures on margin carries a high level of risk, and may not be suitable for all investors. Before deciding to trade, you should carefully consider your objectives, financial situation, needs and level of experience. Pharma Stocks Today provides general advice that does not take into account your objectives, financial situation or needs. The content of this website must not be construed as personal advice. The possibility exists that you could sustain a loss in excess of your deposited funds and therefore, you should not speculate with capital that you cannot afford to lose. You should be aware of all the risks associated with trading on margin. You should seek advice from an independent financial advisor. Past performance is not necessarily indicative of future success

United States Post Office. P.O. Box 184 500 Venetia Rd. Pennsylvania 15367-999

PharmaStocksToday.com is copyright (© 2024) of Anchor IR. All Rights Reserved

×
Phone Icon

Get Breaking Market Updates Sent Right to Your Phone

Enter Your Cell Phone Today to Start